Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases

• Published in: Medical oncology (Northwood, London, England) London, England), 2014-08, Vol.31 (8), p.81-81, Article 81
• Main Authors: Lu, Rui-Nan, Miao, Kou-Rong, Zhang, Run, Hong, Ming, Xu, Ji, Zhu, Yu, Zhu, Hua-Yuan, Qu, Xiao-Yan, Wang, Shuai, Wang, Li, Fan, Lei, Shen, Wen-Yi, Lu, Hua, Qiu, Hong-Xia, Zhang, Xiao-Yan, Chen, Li-Juan, Xu, Wei, Li, Jian-Yong, Wu, Han-Xin, Qian, Si-xuan
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antibodies, Monoclonal - therapeutic use; Female; Graft vs Host Disease - epidemiology; Graft vs Host Disease - prevention & control; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - therapeutic use; Haplotypes; Hematology; Hematopoietic Stem Cell Mobilization - adverse effects; Hematopoietic Stem Cell Mobilization - methods; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - methods; Humans; Internal Medicine; Leukemia - mortality; Leukemia - therapy; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Paper; Pathology; Peripheral Blood Stem Cell Transplantation - methods; Recombinant Fusion Proteins - therapeutic use; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning - methods; Treatment Outcome; Young Adult
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-014-0081-x

Many Chinese patients with hematologic diseases, who need allogeneic hematopoietic stem cell transplantation (HSCT), lack a human leukocyte antigen-matched donor. To save these patients and to avoid collecting donor bone marrow graft, we adopted haploidentical peripheral blood HSCT with granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells as the grafts without ex vivo T cell depletion. Thirty-eight patients were enrolled, and they received myeloablative preconditioning. Thirty-five patients attained a successful neutrophil and platelet recovery. The median time for the neutrophil recovery was 16 days (range of 10–23 days), and the median time for the platelet recovery was 19 days (range of 10–66 days). During the follow-up at a median time of 33.1 weeks (range of 1.1–412.6 weeks), eleven (28.9 %) patients developed aGVHD grade I–II and seven (18.4 %) patients developed aGVHD grade III–IV. The incidence of cGVHD was 27.6 %, and nine (23.7 %) patients died within the first 100 days after transplantation. The cumulative survival proportions at 1 and 2 years were 52.51 ± 8.57 % and 43.76 ± 9.11 %, respectively. These results suggested that the G-CSF-primed peripheral blood stem cell grafts, without in vitro T cell depletion, could be an appropriate stem cell source for Haplo-HSCT.